iclaprim has been researched along with Skin Diseases, Infectious in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charrier, C; Hawser, S; Huang, DB | 1 |
| Huang, D; Lodise, T; Patel, N | 1 |
| Corey, GR; Huang, DB; Noviello, S | 1 |
| Brandt, R; Hadvary, P; Hawser, S; Islam, K; Krievins, D | 1 |
1 review(s) available for iclaprim and Skin Diseases, Infectious
| Article | Year |
|---|---|
Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Folic Acid Antagonists; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Pyrimidines; Skin Diseases, Infectious | 2018 |
1 trial(s) available for iclaprim and Skin Diseases, Infectious
| Article | Year |
|---|---|
Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Skin Diseases, Infectious; Staphylococcus aureus; Vancomycin; Young Adult | 2009 |
2 other study(ies) available for iclaprim and Skin Diseases, Infectious
| Article | Year |
|---|---|
Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.
Topics: Africa; Anti-Bacterial Agents; Asia; Europe; Folic Acid Antagonists; Global Health; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Latin America; Microbial Sensitivity Tests; Middle East; Population Surveillance; Pyrimidines; Skin; Skin Diseases, Infectious; Tetrahydrofolate Dehydrogenase; United States | 2020 |
Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cost Savings; Folic Acid Antagonists; Hospitalization; Humans; Pyrimidines; Skin Diseases, Infectious; Vancomycin | 2018 |